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Abstract: Malignant pleural mesothelioma is usually a fatal disease
and is considered a locally aggressive tumor. Consequently, distant
metastases are very rare and a diffuse involvement of the lung is
seldom reported. However, due to more efficient chemotherapy
protocols and aggressive management strategies including induction
chemotherapy followed by extrapleural pneumonectomy and adju-
vant high-dose hemithoracic radiation therapy, so called trimodality
therapy, survival is prolonged in selected patients. Therefore, new
presentations of the disease are appearing with new diagnostic and
therapeutic challenges. Herein, we report two cases of treated
mesothelioma patients who developed a miliary mesothelioma in the
remaining lung 36 and 41 months after undergoing multimodal
therapy. Diagnostic assessment and therapeutic strategy are dis-
cussed taking into account the different evolutions of each patient.
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Despite recent therapeutic advances, malignant pleuralmesothelioma (MPM) is associated with poor outcome
due to the diffuse nature of the tumor with involvement of the
surrounding structures and local progression of the disease
generally leading to death within 1 year of diagnosis, usually
caused by direct extension of the tumor.1 Typically, distant
metastases are clinically not apparent, especially early in the
course of the disease, although hematogenous metastases to
the contralateral lung, adrenal glands, and liver are found at
autopsy in one-third to one-half of patients.2 Extensive early
pulmonary metastases are seldom reported in MPM, and to
our knowledge, only three cases have been published in the
literature.3 However, in selected mesothelioma patients un-
dergoing aggressive multimodal therapeutic approach with
prolonged survival, recurrences may be characterized by new
presentations of the disease, resulting in new diagnostic and
therapeutic challenges.
Herein, we report two cases of treated mesothelioma
patients who developed a miliary mesothelioma in the re-
maining lung 36 and 41 months after undergoing multimodal
therapy. Diagnostic assessment and therapeutic strategy are




A 71-year-old man presented in December 2006 with a
2-week history of left-sided pleuritic lower chest pain, dys-
pnea on exertion, and cough without sputum. He had a
medical history significant for occupational asbestos expo-
sure for 10 years, a 25 pack-year smoking history, and
well-controlled hypercholesterolemia. Physical examination
revealed a good performance status (PS  0, ECOG classi-
fication), absence of weight loss, and decreased breath sounds
at the lower part of the left hemithorax with dullness to
percussion. A chest radiograph showed a left-sided pleural
effusion confirmed by a computed tomography (CT) of the
chest but without pleural nodules, pleural thickening, or
parenchymal abnormalities. The pleural cavity was assessed
by thoracoscopy showing pleural carcinomatosis suggestive
of primary pleural cancer. The histological findings were
consistent with the diagnosis of epithelial malignant meso-
thelioma. The patient was enrolled in the phase II research
protocol EORTC 08 031 (European Organization for Re-
search and Treatment of Cancer).4 According to the protocol,
the patient received chemotherapy. After three cycles of
chemotherapy combining cisplatinum (75 mg/m2) and pem-
etrexed (500 mg/m2) every 3 weeks, a CT scan evaluation
showed stable disease. Ten weeks later, the patient underwent
a left-sided extrapleural pneumonectomy (EPP) followed by
radiotherapy on the entire hemithorax (54 Gy, 30 fractions).
Follow-up was performed at 3-month intervals during the first
year and every 6 months thereafter. Thirty-two months after
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completion of the trimodality therapy, the patient reported
some weight loss, increasing dyspnea, and right-sided chest
pain. Assessment of the chest by CT showed innumerable
lung nodules with miliary distribution, pleural effusion, and
mediastinal lymphadenopathy (Figure 1). Because of the
extensive smoking history and the presentation thought atyp-
ical for recurrence of MPM, an endobronchial ultrasound
biopsy of the mediastinal lymph nodes was performed (sta-
tions 7 and 4R) with an unanimous diagnosis of metastatic
epithelial mesothelioma from the French mesothelioma panel
of pathologists (MESOPATH) (Figure 2). Despite resuming
chemotherapy using the same initial combination and, after
the failure of three cycles, the introduction of “second-line”
chemotherapy by valproate-doxorubicin combination,5 the
patient died 40 months after the diagnosis.
Case 2
A 64-year-old man with an occupational asbestos ex-
posure, smoking history (40 pack-years), and an otherwise
noncontributory medical history underwent in October 2006 a
medical thoracoscopy for the diagnosis of a right-sided pleu-
ral effusion leading to the diagnosis of epithelial malignant
mesothelioma. After a careful staging and preoperative evalua-
tion, the decision of our multidisciplinary oncologic institutional
team was to proceed with trimodality therapy including three
cycles of chemotherapy (cisplatinum-pemetrexed) started in
November 2006, followed by EPP (February 2007) and
ipsilateral radiotherapy (55 Gy/30 fractions) which was com-
pleted in May 2007. Clinical and radiological follow-up
carried out every 3 months showed no sign of recurrence until
November 2010. The patient then presented with severe
dyspnea at rest with profound hypoxemia and hypocapnia
requiring continuous nasal oxygen supplementation (4 L/min). The
physical examination revealed a 5-cm subcutaneous meta-
static nodule at the level of a former chest tube insertion site
suggestive of mesothelioma recurrence. CT scan of the chest
revealed a miliary metastatic pattern in the remaining lung
(Figure 3). The therapeutic strategy consisted of chemother-
apy using the same cisplatinum-pemetrexed combination
with a CT scan evaluation every two cycles. After the first
two cycles, the patient dramatically improved with a radio-
logical objective response. After six cycles of chemotherapy,
the patient’s ECOG performance status was 0, he was clini-
cally asymptomatic, did not require oxygen supplementation,
and there was complete resolution of the subcutaneous nod-
ule. Figure 4 shows the last CT scan (May 2011) 3 months
after the last cycle of chemotherapy. The patient continues to
be followed every 3 months.
DISCUSSION
MPM, unlike lung cancer, is presumed to progress
locally by invasion of locoregional organs such as pericar-
dium, ipsilateral lung parenchyma, entire pleural cavity, and
FIGURE 1. Case 1: Computed tomography of the chest
showing diffuse parenchymal nodularity on the remaining
lung, lymphangitis, and pleural effusion.
FIGURE 2. Endobronchial ultrasound biopsies at the time of recurrence. A, Representative image of diffuse tubulopapillary
proliferation of mesothelial origin with invasion of the adipose tissue. B, Immunohistochemical staining-diffuse cytoplasmic
and nuclear staining with anticalretinin of mesothelial cells. Few cells are observed between adipocytes (magnification 400).
C, Tubular architecture. Mesothelial cells are cuboid with central round nuclei without mitosis (hematoxylin & eosin stain,
magnification 400).
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chest wall, ultimately leading to the patient’s death. Con-
tralateral lung metastases are rarely identified.3 The treatment
of MPM remains a challenge despite new therapeutic agents
showing efficacy leading to longer survival.
Over the past few years, EPP has played an increas-
ingly important role in the management of MPM for selected
patient.6 This surgical procedure, when compared with pleu-
rectomy/decortication, is thought to decrease the local recur-
rence rate with or without adjuvant hemithoracic radiation.7,8
However, distant recurrences after a bimodality treatment are
frequent as published by several authors.8 These results
provide a rationale for a trimodality therapy combining
chemotherapy to EPP and hemithoracic radiation using a
combination of cisplatinum with pemetrexed or raltitrexed.
Neo- or adjuvant setting of this chemotherapy still remains
undetermined due to the lack of randomized studies.9 How-
ever, in selected patients undergoing such trimodality treat-
ment, prolonged survivals are possible, potentially leading to
late and atypical recurrences diagnosed during the necessary
and continuing follow-up.
In MPM, tumor spread is usually thought to be mainly
localized, but the clinical presentation of our two cases argues
for the possibility of hematogenous or lymphatic spread as
represented by miliary dissemination resulting in respiratory
failure. The same mechanism should be invoked for brain,
bone, or other distant metastases reported by other investiga-
tors.10,11 The disease progression in the presented cases were
different using the same cisplatinum-permetrexed chemother-
apy protocol. In case 1, after two cycles of chemotherapy, the
disease still remained in progression even with a “second-
line” chemotherapy combining doxorubicin and valproate,5
leading to the patient’s death. In case 2, the patient began to
improve after the two first cycles of the same protocol with a
near-complete response after six cycles and still remained a
responder 3 months after the last cycle of chemotherapy. To
our knowledge, this is the first report of late miliary meso-
thelioma in patient undergoing trimodality therapy showing
such a spectacular radiological and clinical response after
retreatment with pemetrexed-based chemotherapy.
Nowadays, there are no known reported phase III
studies defining the role of second-line treatment for MPM.
Retreatment with pemetrexed-based chemotherapy has pre-
viously shown promising results in the literature. Razak et al.
retreated four mesothelioma patients presenting local recur-
rences (24 months for two patients, 33 months, and 72
months after the end of the initial treatment) using the same
pemetrexed-based protocol. Two of them, previously re-
sponders to the first-line treatment, achieved a partial re-
sponse to retreatment, with a time to progression of 5.0 or 8.2
months.12 More recently, Hayashi et al. reported four cases of
patients who had initial durable responses with pemetrexed-
based chemotherapy who were retreated with a similar regimen
upon progression of their mesothelioma.13 Further studies are
needed to conclude that patients with recurrent epithelioid
MPM, initial tumor regression, and a time to progression of 6
months or more after the initial chemotherapy could be good
candidates for such management.
Even though recently published guidelines for the man-
agement of mesothelioma suggest a more conservative approach
confining the indication of EPP to clinical trials,14 there is no
consensus due to the lack of comparative studies. However, the
survey carried out among more than 800 surgeons involved in
FIGURE 3. Case 2: Computed tomography scan of the
chest at admission (November 2010) showing multiple nod-
ules on the left lung.
FIGURE 4. Case 2: Computed tomography scan of the
chest 3 months (May 10, 2011) after the last cycle of che-
motherapy (six cycles). Spectacular improvement of the
chest imaging with complete response.
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the care of mesothelioma patients showed that EPP was believed
to be more effective than pleurectomy/decortications, and the
addition of adjuvant chemotherapy and multimodality therapy
were believed to increase the chance of cure.15 Consequently,
physicians should be aware of the possible atypical presentations
of recurrent MPM in patients undergoing multimodal approach
during the follow-up.
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